Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
No biomarker
Cancer:
Thyroid Gland Papillary Carcinoma
Drug:
Cabometyx (cabozantinib tablet)
(
Multi-tyrosine kinase inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
NCCN
Published date:
04/05/2022
Excerpt:
Thyroid carcinoma - Papillary Carcinoma...Useful in Certain Circumstances...Cabozantinib (category 1) if progression after lenvatinib and/or sorafenib
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login